ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), ...

For patients who have undergone successful catheter ablation for atrial fibrillation, treatment with rivaroxaban does not ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

A new trial co-led by the Ottawa Heart Institute and the Research Institute of the McGill University Health Centre shows that ...

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. | Despite the largely stagnant performance ...

Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group.

Leading heart experts say the results were "somewhat surprising," and their discovery could warrant a conversation with your ...

Thousands of men living with advanced, hormone-sensitive prostate cancer (HSPC) in England and Wales will be able to access Bayer's Nubeqa, after it was recommended for NHS use by reimbursement ...

A new trial co-led by the Ottawa Heart Institute and the Research Institute of the McGill University Health Centre shows that ...

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in ...